BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 36849197)

  • 1.
    Krencz I; Sztankovics D; Sebestyén A; Pápay J; Dankó T; Moldvai D; Lutz E; Khoor A
    Pathol Oncol Res; 2024; 30():1611593. PubMed ID: 38706776
    [No Abstract]   [Full Text] [Related]  

  • 2. Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC.
    John N; Schlintl V; Sassmann T; Lindenmann J; Fediuk M; Wurm R; Douschan P; Zacharias M; Kalson L; Posch F; Absenger G; Brcic L; Jost PJ; Terbuch A
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.
    Yang T; Li W; Huang T; Zhou J
    J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature.
    Sheng J; Pan H; Han W
    Front Immunol; 2023; 14():1181444. PubMed ID: 37153561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 gene amplification and focality: relationship with protein expression.
    Jardim DL; Murugesan K; Elvin JA; Huang RSP; Kurzrock R
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36849197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer landscape of
    Huang RSP; Murugesan K; Montesion M; Pavlick DC; Mata DA; Hiemenz MC; Decker B; Frampton G; Albacker LA; Ross JS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer analysis of
    Huang RSP; Decker B; Murugesan K; Hiemenz M; Mata DA; Li G; Creeden J; Ramkissoon SH; Ross JS
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34130989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.
    Clavé S; Pijuan L; Casadevall D; Taus Á; Gimeno J; Hernández-Llodrà S; Rodríguez-Rivera M; Lorenzo M; Menéndez S; Albanell J; Espinet B; Arriola E; Salido M
    Histopathology; 2018 Jan; 72(2):259-269. PubMed ID: 28795418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
    Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH
    Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of
    Hino K; Nishina T; Kajiwara T; Bando H; Nakamura M; Kadowaki S; Minashi K; Yuki S; Ohta T; Hara H; Mizukami T; Moriwaki T; Ohtsubo K; Komoda M; Mitani S; Nagashima F; Kato K; Yamada T; Hasegawa H; Yamazaki K; Yoshino T; Hyodo I
    JCO Precis Oncol; 2022 Aug; 6():e2200135. PubMed ID: 35952320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
    Murugesan K; Jin DX; Comment LA; Fabrizio D; Hegde PS; Elvin JA; Alexander B; Levy MA; Frampton GM; Montesion M; Roychowdhury S; Kurzrock R; Ross JS; Albacker LA; Huang RSP
    Oncologist; 2022 Sep; 27(9):732-739. PubMed ID: 35598202
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.